---
layout: default
title: 7-Keto-Dehydroepiandrosterone Acetaldehyde Aldoste
parent: 僅模型預測 (L5)
nav_order: 32
evidence_level: L5
indication_count: 0
---

# 7-Keto-Dehydroepiandrosterone Acetaldehyde Aldoste
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Hormonal Complex: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This entry contains a complex mixture of 13 substances — including steroid hormones, a catecholamine, gonadotropins, and biological extracts (e.g., *Sus scrofa* ovary) — with no registered indication in the United States and no DrugBank identifier.
The TxGNN model returned **no predicted indications** for this entry, likely because the compound cannot be mapped to a single node in the knowledge graph.
Without a unified drug identity, original indication, or TxGNN output, a standard repurposing evaluation cannot be completed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None available |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; no actual studies linked) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why This Prediction Cannot Be Assessed

The entry submitted to the pipeline contains 13 distinct chemical or biological entities listed as a single INN string:

> 7-Keto-DHEA · Acetaldehyde · Aldosterone · Androsterone · Cholesterol · Cortisone Acetate · Dopamine Hydrochloride · Estrone · Follitropin · Prasterone (DHEA) · Progesterone · *Sus scrofa* Ovary Extract · Testosterone

This profile is consistent with a **multi-component homeopathic or biological preparation** rather than a single molecular entity. TxGNN operates on individual DrugBank nodes; when no DrugBank ID can be assigned, the model has no anchor point in the knowledge graph and cannot generate scored disease predictions.

Additionally, the lack of a defined mechanism of action and the presence of non-pharmacological components (e.g., acetaldehyde as a trace metabolite, *Sus scrofa* ovary as a biological matrix) further limit computational analysis.

---

## US Market Information

No US NDA, BLA, or homeopathic registration records were retrieved for this entry. The TFDA query (2026-03-24) also returned zero results, confirming no registration in Taiwan.

---

## Safety Considerations

Please refer to the package insert for safety information. No DDI, warning, or contraindication data was available for this entry.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This entry cannot be evaluated as a single repurposing candidate because it represents a mixture of 13 substances without a unified DrugBank identity, no approved indication, and no TxGNN output. Proceeding without resolving the identity problem would produce meaningless results.

**To proceed, the following is needed:**

- **Clarify drug identity**: Determine whether this entry represents a single approved product (e.g., a specific homeopathic formulation) or whether each component should be evaluated separately.
- **Assign DrugBank IDs per component**: Each active substance (e.g., Progesterone → DB00396, Testosterone → DB00624, Prasterone → DB01708) should be individually mapped so TxGNN can generate per-component predictions.
- **Identify the intended original indication**: Without a registered use, the repurposing rationale has no baseline to compare against.
- **Obtain package insert or product monograph**: Required to complete the safety screening (DG001 — currently Blocking severity).
- **Re-run TxGNN per individual component**: Once each substance has a valid DrugBank ID, run the pipeline for each separately and aggregate predictions for shared disease targets.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

